Adverum Biotechnologies - Company & Market Research Reports

Adverum is a gene therapy company that innovate and produce medicines for rare and eye diseases that do not have many existing treatments. Adverum focuses on 7 key areas such as: wAMD, A1T Deficiency, HAE, FA, Severe allergy, Color vision deficiency, and XLRS. Adverum biotechnologies was founded in 2006, and it is headquartered in Menlo park, California. The company was previously known as Avalanche Technologies but changed its name to Adverum Biotechnologies in May 2016. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.

From
From
From
Wet AMD- Pipeline Insight, 2018 - Product Thumbnail Image

Wet AMD- Pipeline Insight, 2018

  • Drug Pipelines
  • 106 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
From
From
From
From
From
From
From
CAR-T Therapies Market, 2018-2030 - Product Thumbnail Image

CAR-T Therapies Market, 2018-2030

  • Report
  • 548 Pages
From
Peanut Allergy - Pipeline Review, H2 2018 - Product Thumbnail Image

Peanut Allergy - Pipeline Review, H2 2018

  • Drug Pipelines
  • 117 Pages
From
Peanut Allergy - Pipeline Review, H1 2018 - Product Thumbnail Image

Peanut Allergy - Pipeline Review, H1 2018

  • Drug Pipelines
  • 107 Pages
From
Peanut Allergy - Pipeline Insight, 2018 - Product Thumbnail Image

Peanut Allergy - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Hypersensitivity - Pipeline Review, H2 2016 - Product Thumbnail Image

Hypersensitivity - Pipeline Review, H2 2016

  • Drug Pipelines
  • 313 Pages
From
From
From
Loading Indicator
adroll